Lisaftoclax is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
| 説明 | Lisaftoclax is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells. |
| ターゲット＆IC50 | Bcl-xL:5.9 nM, Bcl-2:2 nM |
| In vitro | Lisaftoclax shows IC50s of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4 11 cells and Bcl-xl dependent Molm 13 cells[1]. |
| 別名 | APG-2575, Bcl-2/Bcl-xl inhibitor 1 |
| 分子量 | 882.42 |
| 分子式 | C45H48ClN7O8S |
| CAS No. | 2180923-05-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 225mg/mL (255mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
参考文献
投与量変換You can also refer to dose conversion for different animals. 詳細
In vivo投与量計算 (透明溶液)計算器bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lisaftoclax 2180923-05-9 Apoptosis BCL APG-2575 Bcl-2/Bcl-xl inhibitor 1 Inhibitor inhibitor inhibit
